page-template-default,page,page-id-14,bridge-core-2.1.9,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-20.6,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.1,vc_responsive


Vaccibody has been testing it’s lead product candidate, VB10.16, to treat HPV16-induced precancerous cervical lesions in a clinical phase I/IIa study. The study has been completed, and positive 12 months results are available.

Vaccibody is also developing individualised therapeutic cancer vaccines against tumour specific antigens, called neoantigens, arising from somatic gene mutations in malignant cells during neoplastic transformation. The investigational medicinal product (IMP), named VB10.NEO, is intended for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours.

Vaccibody has a clinical collaboration agreement with Nektar Therapeutics for evaluation of Vaccibody’s personalized cancer neoantigen vaccine in combination with Nektar’s CD-122-biased agonist, NKTR-214 in cancer of the head and neck.

Furthermore, Vaccibody has a clinical collaboration agreement with Roche to study VB10.16, Vaccibody’s vaccine directed towards HPV positive cancers in combination with Roche’s checkpoint inhibitor atezolizumab (TECENTRIQ®) in advanced cervical cancer.

Moreover, Vaccibody has compelling preclinical data within cancer and infectious diseases.